Article Type
Changed
Mon, 07/26/2021 - 19:49

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Publications
Topics
Sections

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: HCC August 2021
Gate On Date
Fri, 07/23/2021 - 18:15
Un-Gate On Date
Fri, 07/23/2021 - 18:15
Use ProPublica
CFC Schedule Remove Status
Fri, 07/23/2021 - 18:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article